Intro: The US CFFPR includes data from ~30,000 individuals with cystic fibrosis (CF). We aimed to examine trends in incidence and prevalence alongside screening rates of cystic fibrosis related diabetes (CFRD) from 2003-2018.
Methods: Prevalence of CFRD was defined as the percent of patients with CFRD in the registry in a given year. Annual incidence of CFRD was calculated as the number of new diagnoses per 1,000 person-years. Annual screening rates were defined as the percent of individuals without CFRD who underwent an oral glucose tolerance test (OGTT). Individuals <10 years were excluded, and data were grouped by age decade.
Results: (Table 1) CFRD screening rates increased from 2003-2018, particularly in 10-18 yr olds. Although screening rates increased in adults as well, overall rates remain low. In 10-18 yr olds, the incidence of CFRD did not increase, and incident cases in adults decreased. The prevalence of CFRD is gradually increasing in adults.
Conclusions: Despite increased screening, the incidence of CFRD is stable or declining. CFRD prevalence is steadily rising in older adults. Screening rates and trends in CFRD incidence support a need for revised and potentially targeted screening algorithms. With increasing longevity in people with CF and rising prevalence of CFRD, there is great need for more specialists trained to care for a growing population of adults with CFRD.
C.L.Kohler: None. T.B.Vigers: None. C.Sakamoto: None. A.Moran: Advisory Panel; Abata Therapeutics, Dompé, Other Relationship; Novo Nordisk, Research Support; Abbott Diabetes. S.Sagel: None. C.L.Chan: None.
